Cargando…
Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome
Down syndrome (DS) induces a variable phenotype including intellectual disabilities and early development of Alzheimer’s disease (AD). Moreover, individuals with DS display accelerated aging that affects diverse organs, among them the brain. The Ts65Dn mouse is the most widely used model to study DS...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470680/ https://www.ncbi.nlm.nih.gov/pubmed/35767135 http://dx.doi.org/10.1007/s11064-022-03659-0 |
_version_ | 1784788897037811712 |
---|---|
author | Kirstein, Martina Cambrils, Alba Segarra, Ana Melero, Ana Varea, Emilio |
author_facet | Kirstein, Martina Cambrils, Alba Segarra, Ana Melero, Ana Varea, Emilio |
author_sort | Kirstein, Martina |
collection | PubMed |
description | Down syndrome (DS) induces a variable phenotype including intellectual disabilities and early development of Alzheimer’s disease (AD). Moreover, individuals with DS display accelerated aging that affects diverse organs, among them the brain. The Ts65Dn mouse is the most widely used model to study DS. Progressive loss of cholinergic neurons is one of the hallmarks of AD present in DS and in the Ts65Dn model. In this study, we quantify the number of cholinergic neurons in control and Ts65Dn mice, observing a general reduction in their number with age but in particular, a greater loss in old Ts65Dn mice. Increased expression of the m1 muscarinic receptor in the hippocampus counteracts this loss. Cholinergic neurons in the Ts65Dn mice display overexpression of the early expression gene c-fos and an increase in the expression of β-galactosidase, a marker of senescence. A possible mechanism for senescence induction could be phosphorylation of the transcription factor FOXO1 and its retention in the cytoplasm, which we are able to confirm in the Ts65Dn model. In our study, using Ts65Dn mice, we observe increased cholinergic activity, which induces a process of early senescence that culminates in the loss of these neurons. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11064-022-03659-0. |
format | Online Article Text |
id | pubmed-9470680 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-94706802022-09-15 Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome Kirstein, Martina Cambrils, Alba Segarra, Ana Melero, Ana Varea, Emilio Neurochem Res Original Paper Down syndrome (DS) induces a variable phenotype including intellectual disabilities and early development of Alzheimer’s disease (AD). Moreover, individuals with DS display accelerated aging that affects diverse organs, among them the brain. The Ts65Dn mouse is the most widely used model to study DS. Progressive loss of cholinergic neurons is one of the hallmarks of AD present in DS and in the Ts65Dn model. In this study, we quantify the number of cholinergic neurons in control and Ts65Dn mice, observing a general reduction in their number with age but in particular, a greater loss in old Ts65Dn mice. Increased expression of the m1 muscarinic receptor in the hippocampus counteracts this loss. Cholinergic neurons in the Ts65Dn mice display overexpression of the early expression gene c-fos and an increase in the expression of β-galactosidase, a marker of senescence. A possible mechanism for senescence induction could be phosphorylation of the transcription factor FOXO1 and its retention in the cytoplasm, which we are able to confirm in the Ts65Dn model. In our study, using Ts65Dn mice, we observe increased cholinergic activity, which induces a process of early senescence that culminates in the loss of these neurons. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11064-022-03659-0. Springer US 2022-06-29 2022 /pmc/articles/PMC9470680/ /pubmed/35767135 http://dx.doi.org/10.1007/s11064-022-03659-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Paper Kirstein, Martina Cambrils, Alba Segarra, Ana Melero, Ana Varea, Emilio Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome |
title | Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome |
title_full | Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome |
title_fullStr | Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome |
title_full_unstemmed | Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome |
title_short | Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome |
title_sort | cholinergic senescence in the ts65dn mouse model for down syndrome |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470680/ https://www.ncbi.nlm.nih.gov/pubmed/35767135 http://dx.doi.org/10.1007/s11064-022-03659-0 |
work_keys_str_mv | AT kirsteinmartina cholinergicsenescenceinthets65dnmousemodelfordownsyndrome AT cambrilsalba cholinergicsenescenceinthets65dnmousemodelfordownsyndrome AT segarraana cholinergicsenescenceinthets65dnmousemodelfordownsyndrome AT meleroana cholinergicsenescenceinthets65dnmousemodelfordownsyndrome AT vareaemilio cholinergicsenescenceinthets65dnmousemodelfordownsyndrome |